Title |
Addition of anti‐leukotriene agents to inhaled corticosteroids in children with persistent asthma
|
---|---|
Published in |
Cochrane database of systematic reviews, October 2013
|
DOI | 10.1002/14651858.cd009585.pub2 |
Pubmed ID | |
Authors |
Bhupendrasinh F Chauhan, Raja Ben Salah, Francine M Ducharme |
Abstract |
In the treatment of children with mild persistent asthma, low-dose inhaled corticosteroids (ICS) are recommended as the preferred monotherapy (referred to as step 2 of therapy). In children with inadequate asthma control on low doses of ICS (step 2), asthma management guidelines recommend adding an anti-leukotriene agent to existing ICS as one of three therapeutic options to intensify therapy (step 3). |
X Demographics
The data shown below were collected from the profiles of 74 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 24 | 32% |
Chile | 4 | 5% |
United Kingdom | 2 | 3% |
Saudi Arabia | 1 | 1% |
Argentina | 1 | 1% |
Mexico | 1 | 1% |
Nigeria | 1 | 1% |
Canada | 1 | 1% |
Kuwait | 1 | 1% |
Other | 5 | 7% |
Unknown | 33 | 45% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 61 | 82% |
Practitioners (doctors, other healthcare professionals) | 7 | 9% |
Scientists | 5 | 7% |
Science communicators (journalists, bloggers, editors) | 1 | 1% |
Mendeley readers
The data shown below were compiled from readership statistics for 120 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | <1% |
Colombia | 1 | <1% |
Unknown | 118 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 22 | 18% |
Student > Bachelor | 16 | 13% |
Student > Ph. D. Student | 11 | 9% |
Other | 10 | 8% |
Student > Doctoral Student | 6 | 5% |
Other | 24 | 20% |
Unknown | 31 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 45 | 38% |
Nursing and Health Professions | 16 | 13% |
Social Sciences | 4 | 3% |
Biochemistry, Genetics and Molecular Biology | 3 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
Other | 13 | 11% |
Unknown | 36 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 60. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 December 2023.
All research outputs
#713,565
of 25,460,914 outputs
Outputs from Cochrane database of systematic reviews
#1,328
of 12,090 outputs
Outputs of similar age
#6,030
of 220,224 outputs
Outputs of similar age from Cochrane database of systematic reviews
#30
of 225 outputs
Altmetric has tracked 25,460,914 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,090 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 38.2. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 220,224 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 225 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.